Many patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative (HR+ /HER2−) ABC respond to endocrine therapy (ET), a mainstay treatment for these cancers [2, 3]. Here, ERBB2 is linked to cancer.